Abstracts Archive - Page 309 of 1683 - ATC Abstracts

2021 American Transplant Congress
Mhealth Family Self-Management Intervention for Families of Transplanted Children
S. M. Lerret¹, R. White-Traut², B. Medoff-Cooper³, S. I. Ahamed⁴, P. Simpson⁵, R. Schiffman⁶
¹Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ²Children's Wisconsin, Milwaukee, WI, ³University of Pennsylvania, Philadelphia, PA, ⁴Department of Computer Science, Marquette University, Milwaukee, WI, ⁵Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, ⁶University of Wisconsin Milwaukee, Milwaukee, WI
*Purpose: Nearly 2,000 children undergo solid organ transplant in the US annually. In our previous research with transplant families, parents reported difficulty coping with the…
2021 American Transplant Congress
Frequency and Types of Pharmacist Interventions and Risk Assessments Occurring During the 12-Month Transafe Rx Randomized Controlled Trial
H. M. Gonzales, J. N. Fleming, D. J. Taber
MUSC, Charleston, SC
*Purpose: Clinical pharmacists have unique education and training to identify and mitigate medication (med) safety issues in high-risk populations, such as kidney transplant (KTX). The…
2021 American Transplant Congress
Psychosocial Determinants of Regimen Adherence Among Kidney Transplant Recipients
A. Balakrishnan, S. Bailey, D. Mroczek, M. Serper, D. P. Ladner, M. S. Wolf
Northwestern University, Chicago, IL
*Purpose: There is increasing evidence suggesting a high prevalence of inadequate medication adherence among kidney transplant recipients (KTRs) and its subsequent consequences on health outcomes.…
2021 American Transplant Congress
Outcomes of Hepatitis C Nucleic Acid Testing Positive Donors in Aviremic Recipients With Delayed Direct-Acting Antiviral Initiation
M. Hudson, A. Webb, A. Logan, A. Silverman, A. Brueckner
Pharmacy, Tampa General Hospital, Tampa, FL
*Purpose: The purpose of this study was to assess the clinical impact of utilizing hepatitis C virus (HCV) nucleic acid testing (NAT)+ donors in HCV…
2021 American Transplant Congress
Addressing a Need in Transplant Clinical Care: Creation of the Organ Transplant Caregiver Toolkit
H. Bruschwein¹, G. Chen², A. Ortega³, W. Balliet⁴, T. Coco⁵, C. Thomas⁶, B. Hansen⁵, D. Richardson⁷, K. Canavan⁸, C. Burch⁹, A. Yaldo¹⁰, M. Jesse¹¹
¹University of Virginia School of Medicine, Charlottesville, VA, ²Memorial Hermann Transplant Center, Houston, TX, ³Memorial Transplant Institute, Miami, FL, ⁴Medical University of South Carolina, Charleston, SC, ⁵Mayo Clinic, Pheonix, AZ, ⁶Banner Transplant Institute, Pheonix, AZ, ⁷Caregiver, Minburn, IA, ⁸National Kidney Foundation, New York, NY, ⁹Stanford Children's Hospital, Palo Alto, CA, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Henry Ford Transplant Institute, Detroit, MI
*Purpose: Lay or informal caregivers are a critical component of pre- and post-operative care in adult organ transplantation and living donation. Caregiving in organ transplantation…
2021 American Transplant Congress
Primary Outcome of OPTIMAL: A Prospective Multicenter Trial of Immunosuppression Withdrawal (ISW) in Stable Adult Liver Transplant (LT) Recipients
S. Chandran¹, K. Mason², L. F. Sun¹, N. Tanimine³, M. DesMarais¹, B. Burrell¹, J. F. Markmann³
¹ITN, San Francisco, CA, ²Rho, Inc., Durham, NC, ³MGH, Boston, MA
*Purpose: To identify clinical & mechanistic correlates of successful ISW and operational tolerance (OT) in a selected cohort of adult LT recipients.*Methods: The Immune Tolerance…
2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
G. Gupta, I. Yakubu, P. Kimball, L. Kang, K. Mitchell, M. Shinbashi, D. Kumar, I. Moinuddin, L. Kamal, A. King, C. Bhati, M. Levy, A. Cotterell, A. Sharma, R. Sterling
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
2021 American Transplant Congress
Disparities in Living Donor Follow-up During the COVID-19 Emergency Suspension of OPTN Follow-up Reporting Requirements
S. E. Booker, A. Henderson, L. A. Cartwright, S. Taranto, D. Klassen, J. L. Wainright
UNOS, Richmond, VA
*Purpose: The OPTN temporarily suspended follow-up reporting requirements on 4/3/20 (retroactive to 3/13/20) in response to the COVID-19 crisis. We assessed the policy’s impact on…
2021 American Transplant Congress
Relationship Between %dd-cfDNA, MMDx Molecular Diagnoses, and Donor-specific Antibody in the Trifecta Study
P. F. Halloran¹, L. G. Hildago², J. Reeve¹, Z. Demko³, A. Prewett³, P. Billings³, J. Truong⁴, P. Vander Horn⁴, &. Trifecta Study Group⁵
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Wisconsin, Madison, WI, ³Natera Inc., San Carlos, CA, ⁴One Lambda Inc., West Hills, CA, ⁵., ., AB, Canada
*Purpose: The Trifecta Study is a prospective multicenter investigator-initiated trial to evaluate the relationship between %dd-cfDNA and molecular biopsy findings at the time an indication…
2021 American Transplant Congress
Athena – Effect of Primary Immunosuppression on Development of De Novo Donor Specific Antibodies within First Year After Kidney Transplantation
W. Arns¹, A. Philippe¹, V. Ditt¹, I. A. Hauser¹, F. Thaiss¹, C. Sommerer¹, B. Suwelack¹, A. Finkel², C. Schiedel², D. Dragun¹, B. Nashan¹
¹ATHENA, Study Group, Germany, ²Novartis Pharma GmbH, Nuremberg, Germany
*Purpose: The ATHENA trial [NCT01843348] investigated safety and efficacy of everolimus combined with cyclosporine A [EVR/CsA] or tacrolimus [EVR/TAC] vs. tacrolimus plus mycophenolic acid [MPA/TAC]…